和鉑醫藥-B(2142.HK)領漲生物醫藥B類股 4個交易日累漲36%
格隆匯11月17日丨港股生物醫藥B類股今日普漲,其中,和鉑醫藥一度漲15%至9.12港元,領漲該板塊,且股價已連續四日上漲,創8月初以來新高,4日累漲36%,最新市值67億港元。消息面上,藥物臨牀試驗登記與信息公示平台顯示,和鉑醫藥旗下的HBM4003注射液一項開放性1期研究已於11月8日首次公示,實驗狀態為“進行中 尚未招募”。該試驗旨在評估HBM4003與特瑞普利單抗聯用在晚期肝細胞癌及其他實體瘤患者中的安全性、耐受性、PK/PD和初步療效。


Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.